Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06597396 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
A Phase 2 study of Fatigue Symptom and Post-COVID Condition, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06597396 is a Phase 2 study of Fatigue Symptom and Post-COVID Condition that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 46 participants, below the 65-participant average among 3 other Fatigue Symptom trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06597396, a Phase 2 study of Fatigue Symptom and Post-COVID Condition, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible participants with a confirmed history of COVID19 infection who also have PCC according to the World Health Organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Abrocitinib
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-12-27 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06597396
The ClinicalTrials.gov registry entry for NCT06597396 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 3 other Fatigue Symptom trials with a reported enrollment target (29% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Fatigue Symptom appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06597396 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06597396 about?
NCT06597396 is a clinical study titled "Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID". The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving ove...
What is the current status of trial NCT06597396?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-12-27. Estimated completion is 2026-09-30.
What conditions does trial NCT06597396 study?
This clinical trial studies the following conditions: Fatigue Symptom, Post-COVID Condition.
What interventions are being tested in trial NCT06597396?
The interventions under investigation include: Placebo (DRUG), Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT06597396?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06597396 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue Symptom
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.